WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
Year: 2024
Type: article
Abstract: Focal segmental glomerulosclerosis (FSGS) is a cause of glomerular disease that affects both adults and children. FSGS can rapidly progress to end-stage kidney disease. With no approved treatments there is high unmet need for safe and effective therapies.
Source: Kidney International Reports
Institutions: University of Leicester, Nephrology Center of Maryland, University of Miami, Tufts University, Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Xiamen Innovax Biotech Co., Ltd. (China), Hospital Británico de Buenos Aires, Hospital das Clínicas da Universidade Federal de Pernambuco, St Helier Hospital, Concord Repatriation General Hospital, University Medical Center Groningen
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,800
OpenAlex ID: W4393850280